Peter Beitsch News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Peter Beitsch. Real-time updates on events, politics, business and more.

Agendia, Inc.: Agendia Research Shows Highest Risk MammaPrint Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

May 31, 2023

At the 2023 ASCO® Annual Meeting, Agendia will present data that demonstrates women within MammaPrint's highest risk category have the strongest sensitivity to chemotherapy and more aggressive tumor

United States Kerry Harrington William Audeh Peter Beitsch Agendia Mammaprint Dallas Surgical Group

Source: finanznachrichten.de

Juva Life Files Patent on Family of Non-Cannabinoid Small

October 14, 2021

VANCOUVER, British Columbia, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the...

United States United Kingdom British Columbia Doug Chloupek Los Angeles Peter Beitsch

Source: globenewswire.com

Juva Life : Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications

October 14, 2021

VANCOUVER, British Columbia, Oct. 14, 2021 -- Juva Life Inc.  , a California based life sciences company focused on the research, development, and commercialization of Cannabis products... | October 14, 2021

United States United Kingdom British Columbia Doug Chloupek Los Angeles Peter Beitsch

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Peter Beitsch News Today

Agendia, Inc.: Agendia Research Shows Highest Risk MammaPrint Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

Juva Life Files Patent on Family of Non-Cannabinoid Small

Juva Life : Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications

Explore More Categories